Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a mean » _ mean (Expand Search)
Showing 1,101 - 1,120 results of 118,676 for search '(( a mean decrease ) OR ( 5 ((((ng decrease) OR (a decrease))) OR (we decrease)) ))', query time: 1.64s Refine Results
  1. 1101
    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages.

    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

    Published 2013
    Save to List
    Saved in:
  2. 1102
    IL-17A promotes RANKL-stimulated osteoclastogenesis.

    IL-17A promotes RANKL-stimulated osteoclastogenesis. by Hao Tang (44155)

    Published 2023
    Save to List
    Saved in:
  3. 1103
    Inhibition of autophagy attenuates IL-17A-mediated osteoclastogenesis.

    Inhibition of autophagy attenuates IL-17A-mediated osteoclastogenesis. by Hao Tang (44155)

    Published 2023
    Save to List
    Saved in:
  4. 1104
    Confocal images of oAβ internalization by astrocytes in NG and HG mixed glia cultures.

    Confocal images of oAβ internalization by astrocytes in NG and HG mixed glia cultures. by Yung-Cheng Huang (3443450)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 1105
    Internalized oAβ puncta colocalize with lysosomes in NG and HG mixed glia cultures.

    Internalized oAβ puncta colocalize with lysosomes in NG and HG mixed glia cultures. by Yung-Cheng Huang (3443450)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 1106
    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells.

    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

    Published 2013
    Save to List
    Saved in:
  7. 1107
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 1108
    Simultaneously inhibition <i>Nlu-miR-34</i> and <i>NlInR2</i> in SW strain induced the decrease of SW BPHs.

    Simultaneously inhibition <i>Nlu-miR-34</i> and <i>NlInR2</i> in SW strain induced the decrease of SW BPHs. by Xinhai Ye (6857771)

    Published 2019
    “…<p>(A) Antagomir-34 (with two different quantities) and ds<i>NlInR2</i> (0.84 ng) were injected into the third instar SW strain nymphs, showed that injection of antagomir-34 decreased the ratio of SW type BPH (Chi-square test, 40ng: χ<sup>2</sup> = 5.8, df = 1, <i>p</i> = 0.003; 60ng: χ<sup>2</sup> = 7.9, df = 1, <i>p</i> = 0.042). …”
    Save to List
    Saved in:
  9. 1109
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 1110
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 1111
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 1112
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 1113
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 1114
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 1115
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 1116
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 1117
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 1118
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 1119
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 1120
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: